Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HSAQNYSE:INFUNYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.57-12.0%$1.81$0.17▼$1.99$53.73M0.514.17 million shs52,438 shsHSAQHealth Sciences Acquisitions Co. 2$3.22+3.9%$2.91$9.41▼$13.80$36.10M0.09205,918 shs194,614 shsINFUInfuSystem$6.46+0.9%$5.63$4.61▼$9.97$135.76M1.81102,321 shs125,095 shsNSPRInspireMD$2.26+0.9%$2.47$1.99▼$3.80$69.24M0.5964,193 shs254,752 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-11.99%+13.22%+7.98%+1,558.06%+131.53%HSAQHealth Sciences Acquisitions Co. 20.00%+7.69%+18.38%-27.48%-53.06%INFUInfuSystem+0.94%+4.36%+24.47%+18.10%-1.67%NSPRInspireMD+0.89%-6.61%-9.24%-16.30%-9.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AINFUInfuSystem2.8453 of 5 stars2.03.00.00.02.54.21.9NSPRInspireMD2.5085 of 5 stars3.52.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/AINFUInfuSystem 4.00Strong Buy$13.00101.24% UpsideNSPRInspireMD 3.00Buy$4.5099.12% UpsideCurrent Analyst Ratings BreakdownLatest HSAQ, INFU, NSPR, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,636.04N/AN/A$1.07 per share2.40HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AINFUInfuSystem$137.58M0.99$0.51 per share12.79$2.47 per share2.62NSPRInspireMD$7.03M9.85N/AN/A$1.83 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AINFUInfuSystem$870K$0.14107.6820.84N/A1.12%2.78%1.41%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HSAQHealth Sciences Acquisitions Co. 2N/A0.170.61INFUInfuSystem0.501.981.59NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HSAQHealth Sciences Acquisitions Co. 289.71%INFUInfuSystem71.13%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HSAQHealth Sciences Acquisitions Co. 221.90%INFUInfuSystem11.40%NSPRInspireMD29.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableINFUInfuSystem41021.02 million19.10 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableHSAQ, INFU, NSPR, and CTCX HeadlinesRecent News About These CompaniesInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - MorningstarJune 26 at 1:00 PM | morningstar.comMInspireMD Inc.: InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of StrokeJune 25 at 11:43 AM | finanznachrichten.deFDA grants PMA for InspireMD CGuard Prime carotid stent, triggers $18M milestone paymentJune 25 at 11:43 AM | massdevice.comInspireMD Stock Surges on FDA Approval for CGuard StentJune 24 at 5:53 PM | marketwatch.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of StrokeJune 24 at 4:05 PM | globenewswire.comInspireMD CGuard Prime EPS Carotid Stent System Receives CE Mark ApprovalJune 16, 2025 | evtoday.comEInspireMD Announces CE Mark Approval For CGuard Prime Embolic Prevention SystemJune 15, 2025 | nasdaq.comInspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent SystemJune 15, 2025 | nasdaq.comInspireMD wins CE Mark approval for CGuard PrimeJune 13, 2025 | massdevice.comInspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of StrokeJune 13, 2025 | globenewswire.comInspireMD Hires New Financial ChiefJune 4, 2025 | marketwatch.comInspireMD appoints Michael Lawless CFOJune 4, 2025 | msn.comInspireMD Announces Appointment of Michael Lawless as Chief Financial OfficerJune 3, 2025 | globenewswire.comInspireMD at Bank of America 2025: Carotid Stent InnovationMay 15, 2025 | uk.investing.comEarnings call transcript: InspireMD Q1 2025 shows mixed resultsMay 11, 2025 | uk.investing.comInspireMD, Inc. Reports Q1 2025 Financial Results and Anticipates FDA Approval for CGuard™ Prime Carotid Stent SystemMay 11, 2025 | nasdaq.comInspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comInspireMD Inc.: InspireMD Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deINSPIREMD Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comInspireMD Q1 2025 Earnings PreviewMay 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeToyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock HSAQ, INFU, NSPR, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$2.57 -0.35 (-11.99%) As of 06/25/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ$3.22 +0.12 (+3.87%) As of 06/24/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.InfuSystem NYSE:INFU$6.46 +0.06 (+0.94%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$6.44 -0.02 (-0.31%) As of 06/26/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.InspireMD NYSE:NSPR$2.26 +0.02 (+0.89%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.17 -0.09 (-3.98%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
